Comprehensive Genomic Profiling without Compromise

Oncomine Comprehensive Assay Plus


Common Limitations of Comprehensive Genomic Profiling (CGP)

  • Complicated workflows requiring stitching together up to 5 different instruments and software from up to 5 different suppliers require expertise and extensive hands on time.
  • Some assays are not able to detect mutational signatures relevant for today's precision oncology research such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). Such assays are not comprehensive of increasingly complex and emerging biomarkers.
  • High sample input requirements of some hybrid capture-based NGS assays could result in >57% of samples not being eligible for testing1. With such assays, potentially more than half of the samples will not generate valid results.




On-Demand Webinar Series

Comprehensive Genomic Profiling using the Oncomine Comprehensive Assay Plus

In this webinar series, our speakers will discuss how the Ion Torrent Oncomine Comprehensive Assay Plus eliminates these limitations. They also shared their evaluation of the Oncomine Comprehensive Assay Plus for detection of multi-gene biomarkers, including TMB, MSI, fusion detection as well as homologous recombination repair deficiency (HRD).



From BRCA to HRD
testing in ovarian


Dr. Nicola Normanno, Director, Translational Research, National Cancer Institute, Italy - Pascale Foundation


Clinical Research on Genomic Profiling with Comprehensive Plus


Dr. Ines Raineri, Institute for Pathology Medica AG, Switzerland


Comprehensive Genome Profiling using OCA


Dr. Philip Martin Jermann, Director Molecular Assay Development, University Hospital Basel


Multicentric Study to Evaluate In-house Solution for CGP


Dr. Massimo Barberis, Director of Histopathology and Molecular Diagnostics Unit, European Institute of Oncology, Milan, Italy


Comprehensive Genomic Profiling for HRD


Dr. Andreas Jung, Professor of Molecular Pathology,
University of Munich




Oncomine Comprehensive Assay Plus

The Oncomine Comprehensive Assay Plus is a next-generation sequencing (NGS) solution that enables true comprehensive genomic profiling (CGP) without any compromises.



True End-to-End Workflow

Minimize the resources and expertise required to generate CGP results by combining a highly automated workflow with a complete bioinformatics pipeline all from a single supplier.

Learn More


All Relevant Biomarkers

All relevant single and multiple gene biomarkers including homologous recombination repair (HRR) genes and genomic instability based on loss of heterozygosity (LOH) as well as other mutational signatures.

Learn More


Minimal Sample Input

Only 20 ng of DNA or RNA input will allow up to 98% of samples to be analyzed.

Learn More

True end-to-end
automated workflow

Empower lab efficiency by reducing hands on time and possible errors due to handling. The automated workflow with Ion Torrent Chef and Ion Torrent GeneStudio S5 with dedicated bioinformatics pipelines including Oncomine Reporter means ~1 hour of hands-on time.

True Comprehensive Profiling

Single-gene biomarkers—Broad range of single-gene variants, such as single-nucleotide variants (SNVs), insertions and deletions (indels), novel and known fusions, splice variants, and copy number variants (CNVs), including both copy number gains and losses

Multiple-gene biomarkers—Tumor mutational burden (TMB), predisposition to genetic hypermutability by comparing microsatellite instability (MSI) regions, and analyze mutational signatures for insights into etiological factors in tumorigenesis

Homologous recombination repair deficiency
(HRD)— loss of heterozygosity (LOH) to assess genomic instability and mutations in 42 key genes in the homologous recombination repair (HRR) pathway

Read Article: A Comprehensive Answer for Cancer: Is Comprehensive Genomic Profiling Always the Right Approach?

Tissue is NOT an issue for Oncomine Comprehensive Assay Plus

A multi-center study reported that more than half of all samples would not be suitable for hybrid capture based NGS, while 93.8% of samples below 25mm2 were successfully tested by amplicon based NGS methods.

  • Many clinical research samples are small biopsies core fine-needle aspirates
  • Some NGS methods require as high as 50 to 1,000 ng sample input, which cannot be obtained from small biopsies




HRD & HRR Clinical Research

Homologous recombination repair deficiency (HRD) is becoming an important new biomarker in precision oncology clinical research.Under normal conditions, genes in the homologous recombination repair (HRR) pathway repair DNA damage. Errors in the HRR pathway, such as loss-of-function or deleterious mutations in the associated genes, can lead to higher levels of genomic instability - the HRD phenotype. HRD has been shown to be relevant in certain tumors, such as ovarian and prostate cancers, and is being extensively studied in clinical research.

HRD can be assessed using two main strategies:

  1. Detection of genetic causes, such as germline or somatic mutations of HRR genes.
  2. Evaluation of genomic scaring representing genomic instability: such as analysis of the genome wide loss of heterozygosity (LOH).





Mutation Detection of HRR Pathway Genes

The significant role of HRR genes in maintaining genome stability and tumor suppression has been studied extensively,
especially in the BRCA1 and BRCA2 genes. In recent years, it has been demonstrated that alterations in other homologous recombination repair pathway genes may lead to genomic instability and cancer cell development. The status of HRR genes are now considered an important biomarkers for precision oncology research.




Genomic Instability Measurement

The Oncomine Comprehensive Assay Plus measures genomic instability with both gene-level and sample-level LOH with high accuracy. Figure C demonstrates the LOH assessment at both sample level and gene level compared with Applied Biosystems™ OncoScan™ CNV Assay as an orthogonal test using the same FFPE samples.

Is comprehensive genomic profiling (CGP)
the answer to everything ?

No, one size does not fit all. For example, let’s take non-small cell lung cancer (NSCLC) samples. All biomarkers relevant for clinical research can be tested by one, 50 gene targeted panel. It’s cheaper, faster, and it requires less sample input, which is critical in NSCLC, where “tissue is still an issue”. There are four key scenarios in which comprehensive genomic profiling
would be most impactful.

Learn about them in The Pathologist Article “A Comprehensive Answer for Cancer”.

Learn More

If you are interested in learning more about our Oncomine NGS solutions for comprehensive genomic profiling of solid tumors, a local representation can contact you to set up a demo, or discuss pricing options.




For Research Use Only. Not for use in diagnostic procedures.